PHF20: A Potential Drug Target Or Biomarker for Cancer (G51230)

Target Name: PHF20

NCBI ID: G51230

PHF20

PHF20: A Potential Drug Target Or Biomarker for Cancer

PHF20 (Glioma-expressed antigen 2) is a protein that is expressed in various types of cancer, including glioma, a type of brain cancer. The protein is derived from the glucose-6-phosphate dehydrogenase (G6PD) gene and has been shown to be involved in the development and progression of several types of cancer.

One of the key features of PHF20 is its ability to induce cell death, either through apoptosis or through a process called necroptosis. This is accomplished through the production of reactive oxygen species (ROS), which can damage DNA and cause cell death.

PHF20 has also been shown to be involved in the regulation of cell proliferation. In fact, studies have shown that PHF20 can inhibit the growth of cancer cells and can also induce cell cycle arrest.

Due to its involvement in both cell death and cell proliferation, PHF20 has potential as a drug target or biomarker. For example, it may be used to treat cancers that are characterized by the production of ROS, such as melanoma, breast cancer, and colon cancer.

In addition to its potential as a drug target, PHF20 also has the potential as a biomarker. The ability to induce cell death through ROS production makes it a potential indicator of cancer cell activity. This can be used to monitor the effectiveness of cancer treatments and to identify potential biomarkers for cancer diagnosis.

PHF20 has also been shown to be expressed in various types of cancer cells, including brain cancer cells. This suggests that it may be a useful biomarker for the diagnosis and prognosis of brain cancer.

In conclusion, PHF20 is a protein that has potential as a drug target or biomarker. Its ability to induce cell death through ROS production and its involvement in the regulation of cell proliferation make it a promising target for cancer treatments. Further research is needed to fully understand the role of PHF20 in cancer and to develop effective treatments.

Protein Name: PHD Finger Protein 20

Functions: Methyllysine-binding protein, component of the MOF histone acetyltransferase protein complex. Not required for maintaining the global histone H4 'Lys-16' acetylation (H4K16ac) levels or locus specific histone acetylation, but instead works downstream in transcriptional regulation of MOF target genes (By similarity). As part of the NSL complex it may be involved in acetylation of nucleosomal histone H4 on several lysine residues. Contributes to methyllysine-dependent p53/TP53 stabilization and up-regulation after DNA damage

The "PHF20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHF20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets